The present invention relates to an agent for improving the survival of a lactic acid bacterium and/or a bifidobacterium, which comprises an amino acid as an active ingredient.

The present invention can improve the survival of a lactic acid bacterium and a bifidobacterium, which are probiotics, under acidic environments (i.e., environments having low pH values).

A fermented milk of unheated type that contains lactobacilli, such as bifidus bacterium, excelling in the survival rate of lactobacilli during storage.

According to this method, the extent of reaching the intestine of a bifidobacterium contained in a fermented milk food or drink can be conveniently and accurately evaluated.

Anaeropharma Science Signs Collaborative Research Agreement with Astellas on Creation of Novel Anti-Tumor Drugs Using Bifidobacterium

Backed by 3074 scientific publications out of which more than 1804 are clinical studies, our Bifidobacterium (BB-12®) is the world’s best documented Bifidobacterium

The company aims to leverage the recombinant Bifidobacterium technology named i-DPS to create a new class of anti-cancer drugs.

The large number of scientific publications and clinical studies indicate that Lactobacillus (LA-5®), in combination with Bifidobacterium (BB-12®), may have beneficial gastrointestinal effects:

Under the terms of the agreement, the two companies shall conduct joint research regarding specific substances in order to create drug candidates for cancer therapy that utilizes Bifidobacterium as a drug delivery carrier.

Under the terms of the agreement, the two companies shall conduct joint research regarding specific substances in order to discover novel anticancer agent candidates that utilize Bifidobacterium as a drug delivery system.